A 51-year-old man who was hepatitis B surface antigen (HBsAg)-negative and positive for anti-hepatitisB surface antigen (anti-HBs) and anti-hepatitis B core antigen (anti-HBc), during rituximab therapy for chronic Lymphocytic leukemia, developed reactivation of hepatitisB virus (HBV) infection with hepatitis that proceededtowards hepatic failure and death in spite of lamivudine therapy. HBsAg remained persistently negative, notwithstanding a high HBV-DNA titer. Our observation, following other cases of fatal reactivation of HBV infection in patients receiving rituximab, suggests that, in all patients with previous markers of HBV infection, lamivudine prophylaxis should be considered during rituximab therapy. © Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2005.
Sarrecchia, C., Cappelli, A., Aiello, P. (2005). HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. JOURNAL OF INFECTION AND CHEMOTHERAPY, 11(4), 189-191 [10.1007/s10156-005-0385-z].
HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb
SARRECCHIA, CESARE;
2005-01-01
Abstract
A 51-year-old man who was hepatitis B surface antigen (HBsAg)-negative and positive for anti-hepatitisB surface antigen (anti-HBs) and anti-hepatitis B core antigen (anti-HBc), during rituximab therapy for chronic Lymphocytic leukemia, developed reactivation of hepatitisB virus (HBV) infection with hepatitis that proceededtowards hepatic failure and death in spite of lamivudine therapy. HBsAg remained persistently negative, notwithstanding a high HBV-DNA titer. Our observation, following other cases of fatal reactivation of HBV infection in patients receiving rituximab, suggests that, in all patients with previous markers of HBV infection, lamivudine prophylaxis should be considered during rituximab therapy. © Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2005.| File | Dimensione | Formato | |
|---|---|---|---|
|
fulltext1.pdf
accesso aperto
Licenza:
Creative commons
Dimensione
259.3 kB
Formato
Adobe PDF
|
259.3 kB | Adobe PDF | Visualizza/Apri |
Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons
